Stockscreener 앱 받기
4.59
1.55%
0.07
전일 마감가:
$4.52
열려 있는:
$4.51
하루 거래량:
157.13K
Relative Volume:
0.86
시가총액:
$238.31M
수익:
$3.50M
순이익/손실:
$-80.40M
주가수익비율:
-1.7852
EPS:
-2.5711
순현금흐름:
$-29.83M
1주 성능:
+0.22%
1개월 성능:
-15.16%
6개월 성능:
+33.43%
1년 성능:
+148.11%
1일 변동 폭
$4.50
$4.95
1주일 범위
$4.39
$5.0935
52주 변동 폭
$1.305
$7.75
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
명칭
Camp 4 Therapeutics Corp
전화
617-651-8867
주소
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
4.59 | 234.68M | 3.50M | -80.40M | -29.83M | -2.5711 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-05-27 | 개시 | Wedbush | Outperform |
| 2024-11-05 | 개시 | JP Morgan | Overweight |
| 2024-11-05 | 개시 | Piper Sandler | Overweight |
| 2024-11-05 | 개시 | William Blair | Outperform |
| 2022-08-16 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2021-12-22 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2021-09-24 | 재확인 | Craig Hallum | Buy |
| 2021-06-25 | 재확인 | Craig Hallum | Buy |
| 2020-12-18 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2020-04-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-03-05 | 재확인 | Craig Hallum | Buy |
| 2019-12-20 | 재확인 | Craig Hallum | Buy |
| 2019-12-20 | 다운그레이드 | First Analysis Sec | Outperform → Neutral |
| 2019-06-28 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2019-05-29 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-05-01 | 재확인 | Craig Hallum | Buy |
| 2019-03-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-01-25 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-12-21 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2018-12-14 | 재확인 | B. Riley FBR | Buy |
| 2018-12-11 | 다운그레이드 | First Analysis Sec | Strong Buy → Outperform |
| 2018-12-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2018-11-27 | 개시 | Goldman | Neutral |
| 2018-10-15 | 개시 | Jefferies | Hold |
| 2018-09-28 | 재확인 | Craig Hallum | Hold |
| 2018-04-27 | 재확인 | Craig Hallum | Hold |
| 2018-03-08 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2018-02-16 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
모두보기
Camp 4 Therapeutics Corp 주식(CAMP)의 최신 뉴스
Camp4 Therapeutics Corp boosts team engagement with employee event on the slopes - Traders Union
Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating By Investing.com - Investing.com Australia
Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating - Investing.com
Life sciences leaders unite at Camp4 Therapeutics Corp-backed event supporting health equity - Traders Union
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
CAMP Technical Analysis | Trend, Signals & Chart Patterns | CAMP4 THERAPEUTICS CORP (NASDAQ:CAMP) - ChartMill
Camp4 Therapeutics Corp advances creative strategies in complex drug discovery partnerships - Traders Union
Camp4 Therapeutics (CAMP) grants 170,000 stock options to Chief Scientific Officer - Stock Titan
Camp4 Therapeutics (CAMP) CMO receives 215,000 stock options grant - Stock Titan
Camp4 Therapeutics (CAMP) CFO receives 215,000 stock options grant - Stock Titan
Camp4 Therapeutics Corp (CAMP) CEO granted 580,000 stock options at $4.46 - Stock Titan
Camp4 Therapeutics (CAMP) director awarded 56,000 stock options at $4.46 strike - Stock Titan
Camp4 Therapeutics (CAMP) director Michael MacLean files initial Form 3 - Stock Titan
Amazon To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday - Sahm
Leerink raises CAMP4 Therapeutics price target on CMP-002 progress By Investing.com - Investing.com South Africa
Leerink raises CAMP4 Therapeutics price target on CMP-002 progress - Investing.com
CAMP PE Ratio & Valuation, Is CAMP Overvalued - Intellectia AI
Aug Swings: Should value investors consider Camp4 Therapeutics Corporation2026 Earnings Surprises & Daily Entry Point Alerts - baoquankhu1.vn
CAMP4 Therapeutics Adds Veteran CFO MacLean to Board - TipRanks
CAMP4 Therapeutics Corporation Files Form 8-K for NASDAQ Listing – Company Details and Key Information (March 2026) - Minichart
CAMP4 Appoints Michael MacLean to its Board of Directors - Bitget
Camp4 Therapeutics appoints Michael MacLean to board and expands director compensation - Investing.com Australia
Camp4 Therapeutics appoints Michael MacLean to board and expands director compensation By Investing.com - Investing.com South Africa
CAMP4 Therapeutics appoints Michael MacLean to board of directors - investing.com
CAMP4 Therapeutics appoints Michael MacLean to board of directors By Investing.com - Investing.com UK
Camp4 Therapeutics appoints Michael MacLean as director, joins Audit and Compensation Committees - TradingView
Camp4 Therapeutics Corp adds veteran leader to accelerate regRNA-based therapy clinical push - Traders Union
New CAMP4 (NASDAQ: CAMP) director MacLean joins, receives option grant - Stock Titan
If You Invested $1,000 in Camp4 Therapeutics Corp. (CAMP) - Stock Titan
Camp4 Therapeutics (CAMP) holder Enavate cuts stake to 4.8% of shares - Stock Titan
EVTL Technical Analysis & Price Forecast - Intellectia AI
Camp4 Therapeutics: Strong Cash Runway As CMP-002 Moves Toward Human Trials (NASDAQ:CAMP) - Seeking Alpha
CAMP4 to Participate in Upcoming Investor Conferences - The Manila Times
Biotech firm CAMP4 lines up 3 healthcare investor events - Stock Titan
Cantor Fitzgerald reiterates Overweight on CAMP4 stock, $7 target - Investing.com India
Cantor Fitzgerald reiterates Overweight on CAMP4 stock, $7 target By Investing.com - Investing.com Australia
CAMP4 Highlights 2025 Results and SYNGAP1 Program Progress - TipRanks
Camp4 Therapeutics Corp posts full year 2025 financial results and unveils corporate update - Traders Union
Camp4 Therapeutics Earnings Review: Q4 Summary - Benzinga
Camp4 Therapeutics Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights - GlobeNewswire
Guidance Update: What is Camp4 Therapeutics Corporations book value per shareEarnings Risk Summary & Reliable Price Breakout Alerts - baoquankhu1.vn
Regulatory RNA strategy presented for gene expression, Camp4 Therapeutics Corp outlines - Traders Union
Camp4 Therapeutics Corporation announced that it has received $100.167156 million in funding from Janus Henderson Investors, Balyasny Asset Management L.P., Vivo Capital, LLC, Adage Capital Management, L.P., Trails Edge Capital Partners, LLC, SYN - marketscreener.com
Camp4 Therapeutics Corp unveils ASO approach to boost gene expression in SYNGAP1 treatment - Traders Union
Camp4 Therapeutics Corp commits to new therapies for rare and neurological diseases - Traders Union
CAMP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
RBOT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Analysts Have Conflicting Sentiments on These Healthcare Companies: Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA) - The Globe and Mail
Merger Talk: Whats next for Mondelez International Inc stockQuarterly Profit Review & Verified Chart Pattern Signals - baoquankhu1.vn
Camp 4 Therapeutics Corp (CAMP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):